Physicians promote melanoma screening strategies for people at high-risk
the ONA take:
According to a recent clinical review published in The Journal of the American Medical Association, physicians from Moffitt Cancer Center in Tampa, Florida, suggest that melanoma screening strategies may be more feasible by focusing on high-risk populations and using newer diagnostic tools, and should include efforts to educate the general population about the importance of skin cancer screening.
Their recommendations are based on two studies. The first of which was an Australian melanoma screening study that supports more extensive high-risk population-based screening strategies.
In that study, researchers gave 311 people who had an increased risk of developing melanoma extensive skin screenings every 6 months. The researchers detected 75 melanomas over a mean follow-up of 3.5 years without increasing the number of unnecessary biopsies. The second study conducted in Germany initiated a comprehensive skin screening program.
The researchers in that study observed 48% reduction in melanoma-related deaths after its initiation. The Moffitt physicians also note that physicians must be trained to perform skin examinations and be able to recognize the early stages of melanoma.
Patients at high-risk for developing the disease should be examined by experienced dermatologists.
Melanoma screening strategies may be more feasible by focusing on high-risk populations.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|